Royalty Pharma (RPRX) EPS (Basic) (2020 - 2026)

Royalty Pharma (RPRX) posted EPS (Basic) of $1.07 for Q1 2026, up 29.46% sequentially from $0.83 in Q4 2025, and up 7.46% YoY from $1.0 in Q1 2025.

Analysis

Royalty Pharma (RPRX) EPS (Basic) (2020 - 2026) Analysis & Trends

Royalty Pharma has reported EPS (Basic) for 7 years, with the latest figure at $1.07 in Q1 2026.

Quarterly EPS (Basic) rose 7.46% year-over-year to $1.07 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.11 (down 23.43% YoY) and the FY2025 annual result came in at $3.08, up 3.76% from the prior year.
EPS (Basic) grew to $1.07 in Q1 2026 per RPRX's latest filing, from $0.83 in the prior quarter.
Over five years, EPS (Basic) peaked at $1.8 in Q3 2024 and troughed at -$1.39 in Q4 2022.
A 5-year average of $0.67 and a median of $0.78 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2025: EPS (Basic) sank 1176.48% in 2022, then jumped 10573.77% in 2025.
Over 5 years, EPS (Basic) stood at -$1.39 in 2022, then soared by 215.1% to $1.6 in 2023, then sank by 53.47% to $0.75 in 2024, then climbed by 11.0% to $0.83 in 2025, then grew by 29.46% to $1.07 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered $1.07, $0.83, and $1.03 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	12.62
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	7.70
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-3.06
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.18
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.06
10	Incyte	25.44 Bn	20.91 Bn	1.57 Bn	2.92

Historic Data

Download Data